Table 1.
Characteristics of studies included in the meta-analysis
| Study | Year | Type of study | Country | Duration, month | Dose, mg/day | Number of patients in treatment group (dropouts) | Number of patients in placebo group (dropouts) | Design | Blinding | Allocation concealment, yes/no | Sample size calculations in article, yes/no | Intention-to-treat analysis, yes/no | Inclusion of diabetics, yes/no | Histological scoring system used |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pioglitazone | ||||||||||||||
| Sanyal et al.24 | 2010 | Multicentre | US | 24 | 30 | 80 (14) | 83 (12) | Randomised, placebo-controlled | Double-blind | Yes | Yes | Yes | No | Kleiner et al.13 |
| Aithal et al.22 | 2008 | Multicentre | UK | 12 | 30 | 37 (6) | 37 (7) | Randomised, placebo-controlled | Double-blind | Yes | Yes | No | No | Promrat et al.12 |
| Belfort et al.23 | 2006 | Multicentre | US | 6 | 45 | 26 (3) | 21 (4) | Randomised, placebo-controlled | Double-blind | Yes | Yes | Yes | Yes | Kleiner et al.13 |
| Rosiglitazone | ||||||||||||||
| Ratziu et al.25 | 2008 | Single centre | France | 12 | 4 × 1 month then 8 × 11 months | 32 (1) | 31 (0) | Randomised, placebo-controlled | Double-blind | Yes | Yes | Yes | Yes | Brunt et al.11 and Kleiner et al.13 |
US, United States; UK, United Kingdom.